

CUE Growth Partners Launches and Completes Disruptive Med Tech Investment Shortly Thereafter
March 24, 2023

CUE Growth launched as a healthcare investment firm with two complementary asset classes, late-stage Venture Capital and Lower Middle Market Private Equity, to invest in specific areas of healthcare innovation and related value-added services. Our focus areas include med device & related value-added services and provider software & tech-enabled physician services. We pursue opportunities to deploy \$10-30 million of equity per late-stage VC investment as a bridge to a strategic-sale, and up to \$100 million of equity per PE investment often with strategic-sale optionality.

Within weeks of launching, Cue Growth's differentiated relationships with operators and clinicians in healthcare led to its significant investment in disruptive med tech company, Amplitude Vascular Systems ("AVS"). AVS is the only intravascular lithotripsy ("IVL") alternative (tested in humans) to a high-flyer in the public markets that recently garnered an approx. \$10 billion market capitalization on a similar and singular medical technology. More importantly, the AVS Pulse System, a combination of hardware, software and a disposable catheter, has the opportunity to save potentially millions of people from coronary (heart) and peripheral (limbs) vascular disease due to calcified arteries.

"It's truly an honor to invest in a leading platform in a relatively new medical technology driving rapid penetration in the largest area of healthcare (cardiovascular medicine) that has attracted interest from many large, public med tech strategics and multi-billion dollar healthcare funds," mentioned Co-Founder, Ben Cannon, "and only two investment firms in CUE Growth and Biostar Capital were positioned well-enough to complete the entire growth capital infusion, which is a testament to those around our platform."

The AVS executive team includes the CEO behind the #2 most innovative med tech company in the world (Fast Company 2023), and separately, an executive who has run one of the largest, public med tech companies, along with other resources who have successfully scaled med tech companies to a strategic sale or public offering.

"We were privileged to have The Wall Street Journal ("WSJ") recognize med device as a defensive and attractive category, particularly as the market outlook weakens," mentioned Co-Founder Alyssa Murstein, "and to have the WSJ, among 12 other publications, highlight AVS as a recent and category defining example is a cherry on top. Though AVS has much to do and is still relatively early in the development lifecycle, we look forward to continuing to support the company and its leadership."

About CUE Growth Partners

CUE Growth is a healthcare investment firm with two complementary asset classes, late-stage Venture Capital and Lower Middle Market Private Equity, to invest in specific areas of healthcare innovation and related value-added services. Our focus areas include med device & related services and provider software & tech-enabled physician services. We pursue opportunities to deploy \$10-30 million of equity per late-stage VC investment as a bridge to a strategic-sale, and up to \$100 million of equity per PE investment often with strategic-sale optionality.